Breaking News

Ligand, ABBA Enter OmniAb Platform Pact

Licenses platform to generate fully human mono- and bispecific antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing immuno-oncology therapies, under which ABBA will be able to use the OmniRat, OmniMouse and OmniFlicplatforms to generate fully human mono- and bispecific antibodies. Ligand will receive an initial access payment, and will be eligible to receive clinical milestones and royalties for each successful OmniAb antibody. ABBA will be responsible for all program ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters